One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Adial Pharmaceuticals, Inc.
ADIL · NCM · Healthcare · Biotechnology
Current price
$3.50
52-week range
$1.31 - $10.25
Market cap
$9.19M
Balance sheet
Healthy
-52.15x Concerning
Net cash $28.71M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is developing medicines to help people struggling with addiction, like alcohol use disorder. Their main focus is on a potential treatment called AD04, which is currently in late-stage testing. This matters because if approved, it could offer a new option for millions of people seeking help.
How the company got here
Adial Pharmaceuticals was founded in 2010 with the goal of developing targeted therapies for addiction and related disorders. The company's initial focus was on alcohol use disorder (AUD), with its lead drug candidate, AD04, being a serotonin-3 antagonist designed for patients with specific genetic markers. A significant turning point for Adial was the acquisition of Azora Therapeutics in June 2026. This strategic move expanded Adial's pipeline beyond addiction treatments into inflammatory diseases, specifically ulcerative colitis, with the addition of the drug candidate AT177. This acquisition also brought new management talent and a separate financing vehicle into the company, reshaping its strategic direction and broadening its therapeutic areas.
What it actually does
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company. This means it is in the process of testing new medicines to see if they are safe and effective, rather than selling approved drugs. The company focuses on developing treatments for addiction and related disorders, as well as serious inflammatory diseases. Its approach involves precision medicine, which means tailoring treatments to individual patients based on their genetic makeup or other specific characteristics.
Alcohol Use Disorder (AUD) Therapeutics
Adial's original focus was on developing treatments for Alcohol Use Disorder (AUD), a condition characterized by an impaired ability to stop or control alcohol use despite adverse social or health consequences. Their lead drug candidate in this area is AD04, which is a type of drug called a serotonin-3 antagonist. This drug is designed to be genetically targeted, meaning it is intended for patients who have specific genetic profiles that are believed to make them more responsive to the treatment. AD04 has been investigated in Phase 3 clinical trials, which are large-scale studies to confirm a drug's effectiveness and safety before it can be approved by regulatory bodies like the FDA.
Ulcerative Colitis (UC) Therapeutics
Through its acquisition of Azora Therapeutics in June 2026, Adial expanded into the treatment of inflammatory diseases, with a particular focus on ulcerative colitis (UC). Ulcerative colitis is a chronic inflammatory bowel disease that causes inflammation and ulcers in a person's digestive tract. Adial's drug candidate for UC is AT177, which is described as a colon-targeted aryl hydrocarbon receptor (AhR) agonist. This means AT177 is designed to deliver its therapeutic effect directly to the colon, where the inflammation in UC primarily occurs, with the aim of minimizing exposure to the rest of the body. AT177 is currently in the early stages of development, with plans for further clinical studies.
What management is betting on now
Adial's current strategy is centered on advancing its two main drug candidates, AD04 for alcohol use disorder and AT177 for ulcerative colitis. The company is focusing on a precision medicine approach, using genetic targeting to identify patients most likely to benefit from AD04. For AT177, the strategy involves developing a colon-targeted therapy to address the specific needs of ulcerative colitis patients. Management is also focused on strengthening the company's financial position through financing activities to support these clinical development programs and building long-term value for patients and shareholders.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
—
Net income
$-51.99M
Diluted EPS
-11.25
Operating cash flow
$-6.36M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.02M
Diluted EPS
-1.48
Operating cash flow
$-1.61M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.00M
Diluted EPS
-11.33
Operating cash flow
$-1.32M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-1.79M
Diluted EPS
-0.08
Operating cash flow
$-1.83M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-1.96M
Diluted EPS
-0.18
Operating cash flow
$-1.75M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.23M
Diluted EPS
-0.34
Operating cash flow
$-1.59M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.07M
Diluted EPS
0.44
Operating cash flow
$-1.45M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.19M
Diluted EPS
-0.38
Operating cash flow
$-1.69M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $3.50
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $28.7M - more cash than debt. Interest coverage -52.1x.
Net debt
$-28.71M
Interest coverage
-52.15x
Adial Pharmaceuticals, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 2 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
ADIL
BASELINE
Adial Pharmaceuticals, Inc.
Total debt $0.00 Interest coverage -52.15x This is the baseline the peer rows are being compared against.
Total debt $2.68M Interest coverage -58.49x Neither company has much profit cushion over interest right now.
Total debt $577.00K Interest coverage -11,392.67x Neither company has much profit cushion over interest right now.
Total debt $8.36B Interest coverage 9.23x This peer still has a real interest-payment cushion, while ADIL does not.
Total debt $2.99B Interest coverage 1.99x This peer still has a real interest-payment cushion, while ADIL does not.
What you should know
The case for and against ADIL
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -2011.6% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.47x
P/B
-0.24x
P/S
—
EV/EBITDA
-1.65x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-2,011.6%
ROA
-40.0%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
5.63x
Quick ratio
5.61x
Total debt
$0.00
Total cash
$28.71M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-20.65
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-11.13M
Free CF TTM
$-6.49M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—